Mitotix

Mitotix was a biotechnology company focused on the discovery and development of therapeutics targeting the cell cycle. Founded in 1992 and based in Cambridge, Massachusetts, the company specialized in identifying small molecule inhibitors of cyclin-dependent kinases (CDKs), which are critical regulators of cell division. Their research was primarily directed toward oncology, aiming to halt the uncontrolled proliferation of cancer cells. Mitotix successfully established several high-profile collaborations with pharmaceutical leaders such as Bristol Myers Squibb and DuPont Pharmaceuticals. In 2000, the company was acquired by GPC Biotech for approximately $135 million in stock, integrating its cell cycle expertise into GPC's drug discovery platform.